Faecalibacterium species

**Faecalibacterium species** refers to a *genus* of gram-positive-like, obligately anaerobic, rod-shaped bacteria that are a dominant component of the human gut microbiota, most notably represented by Faecalibacterium prausnitzii and several other recently characterized species including F. duncaniae, F. longum, F. hattorii, F. butyricigenerans, and F. gallinarum[1][2][3][4]. These bacteria are non-motile, non-spore forming, and thrive in the colon where they ferment dietary fiber, primarily producing butyrate—a short-chain fatty acid crucial for colonic epithelial energy supply and gut homeostasis[1][3][4]. Faecalibacterium exerts beneficial *anti-inflammatory* effects, in part by secreting bioactive molecules (e.g., microbial anti-inflammatory molecule, MAM)[2][6]. Reduced levels of Faecalibacterium, especially F. prausnitzii, are strongly associated with inflammatory bowel disease, colorectal cancer, and several other inflammatory conditions, supporting its potential as a *microbiome-based biomarker* for gut health and as a promising next-generation probiotic (NGP)[6][1][5][4]. The genus exhibits considerable genetic and functional diversity, with several species and strains differing in anti-inflammatory capacity, butyrate production, and adaptation to specific ecological niches in the gut[2][4]. Current research highlights its general safety and beneficial properties, but thorough strain-specific safety assessment is necessary for therapeutic development due to potential antibiotic resistance or undesired genetic elements in some strains[5][4]. Notes: - The query "Fecalibacterium species" is ambiguous and *not a canonical molecular target*: it refers to a bacterial genus, not a druggable molecule such as an enzyme, receptor, transporter, etc. [is_incorrect: true] - The appropriate use is at the genus or species level (e.g., Faecalibacterium prausnitzii), not as a molecular target. - Functional analysis and therapeutic considerations apply to the bacteria as living biotherapeutics or probiotics, not as cell-surface or intracellular molecular targets. Faecalibacterium is not a molecular target such as a receptor, enzyme, or transporter but rather a microbial taxonomic group of interest for microbiome-based approaches to health and disease[6][1][2][4].

Other names

Faecalibacterium genusFaecalibacterium spp.F. prausnitzii group